Effects of a soybean isoflavone metabolite on male osteoporosis and the elucidation of its mechanism

点击翻译按钮获取中文摘要

The administration of equol (0.50 mg/day) for 4 weeks inhibited tibial bone loss, and markers of bone resorption tended to decrease in orchiectomized mice. Furthermore, equol significantly inhibited the osteoclast formation induced by RANKL (receptor activator of NF-kappaB ligand) in a dose-dependent manner (0.1-50 μM) in RAW 264 cells and promoted the activities of caspase 3/7 in RAW 264 cell-derived mature osteoclasts. These results suggest that equol improves the bone metabolism in male osteoporotic patients, and the inhibition of bone resorption may contribute to the improvement of bone metabolism.